ROSESELSA, a Leading Chinese Hi-Fi Brand and East Asian Audio Equipment Pioneer, Launches Its Groundbreaking OPENFREE Clip-On Wireless Earbuds Globally
Continue Reading
OPENFREE clip-on open-ear wireless earbuds by ROSESELSA, shown in a minimalist product photo.
A proprietary "Suspension + Micro-Clip" Structure delivers an air-light, secure fit that defies perception. The breakthrough 10mm Liquid Crystal Composite Diaphragm and Planck Driver technology shatter the sound quality barriers of open-ear designs. Dual LDAC and LHDC High-Fidelity Audio codec support reveals near-CD-quality lossless detail across every note. Ultra-low 20ms latency via the LC3 protocol ensures perfect audio-visual synchronization for gaming and video.
Founded in 2015, ROSESELSA drew inspiration from the Buddhist philosophy "Amidst a sea of choices, I take but one." Embracing a "small yet exquisite" ethos, the brand dedicated itself to the audio industry. Driven by the spirit of "Dare to be Different," ROSESELSA pursues relentless innovation. Through its highly popular products, the brand has steadily expanded its footprint and influence within Mainland China. In 2023, ROSESELSA appointed the renowned musician Steve Chou as Brand Ambassador for Mainland China. His profound musical literacy and unique personal style further strengthened ROSESELSA's brand image of exceptional sound quality and distinctive style.
Over the past three years, ROSESELSA has championed its "Democratizing Premium Sound" philosophy, enabling users to access high-end audio experiences at affordable prices. The brand constantly secured the Top 1 on the east Asian audio equipment charts, and achieved sales revenue of CNY 162 million (approx. US$22.5 million ) during the 2025 618 Shopping Festival, cementing its industry leadership position.
In 2024, ROSESELSA launched its global expansion strategy, actively entering key markets across Europe , North America , and the Asia-Pacific region. Its exceptional headphone portfolio garnered significant global attention across digital platforms and won multiple prestigious international design awards, including the Silver Winner MUSE Design Awards, New York Product Design Awards (NYPDA), and the London Design Awards.
"We remain true to our founding spirit, and combine original design with modern simplicity. By continuously creating classic, memorable products in this era of rapid obsolescence, we try to bring surprise and touch to users worldwide," says Jack Long , the CEO of ROSESELSA.
Media Contact: Henry Chen , [email protected]
SOURCE ROSESELSA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
18 minutes ago
- Cision Canada
DXC Ranked a Leader in ISG Provider Lens™ Snowflake Ecosystem Partners 2025 Study
DXC is ranked a Leader in ISG's Provider Lens™ Snowflake Ecosystem Partners 2025 study across all categories in the US and Europe. The study evaluates providers' ability to advise clients on Snowflake ecosystem strategy, modernize data landscapes, enable advanced analytics, and manage the Snowflake environment. DXC's data-centric strategy, Gen AI-led transformations, streamlining and automating migrations, cost-optimized data ingestion, and workforce training and development were highlighted by ISG. ASHBURN, Va., July 22, 2025 /CNW/ - DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today was recognized as a Leader by ISG, a leading global technology research and advisory firm, in its Provider Lens™ Snowflake Ecosystem Partners 2025 study across all categories in the US and Europe. The recognition highlights DXC's strengths in data-centric strategy, Gen AI-led transformations, streamlining and automating migrations, cost-optimized data ingestion, and workforce training and development. "DXC brings a robust, well-rounded, and end to-end Snowflake capability suite, combining deep advisory expertise, industry-specific implementations, GenAI integration, and strong managed services including MLOps integration," said Santhosh Alby, Lead ISG Analyst. "The company's work is reinforced by a culture of innovation and continuous learning to deliver scalable, secure, and future-ready data platforms." Snowflake is a leading cloud data platform that enables more than 11,000 companies worldwide to build, use, and share data, applications, and AI. DXC and Snowflake have collaborated to deliver advanced data-driven and AI solutions, including a connected mobility analytics solution for automotive. The 2025 Snowflake Ecosystem Partners study evaluates providers' ability to advise clients on Snowflake ecosystem strategy, modernize data landscapes, enable advanced analytics, and manage the Snowflake environment. The report highlights DXC's strengths across three categories: Consulting and Advisory Services – DXC's strength in legacy migrations, designing data strategies to minimize risk, and implementation and change management helps enterprises maximize ROI from Snowflake investments. Implementation Services – DXC's comprehensive Snowflake implementation services enable enterprises to accelerate migrations, optimize costs, and efficiently manage security and compliance across data. Managed and Support Services – DXC supports Snowflake ecosystems with security and governance compliance, automated resource scaling, metadata-driven data ingestion, and anomaly detection. "Snowflake plays a pivotal role in modern data management and analytics, allowing us to deliver faster, smarter solutions for our customers by combining data, AI, and governance in one platform," said Pete McEvoy, Managing Director and Global Data AI Head at DXC. "Our investment in the Snowflake ecosystem underscores our commitment to delivering AI-led and data-driven efficiencies that move our customers forward. This recognition from ISG reinforces the impact of our strategy and the value we're creating for our customers." The study also showcases DXC's emphasis on training and development, providing 24/7 access to over two million learning assets via the DXC Learning Platform. Additionally, DXC Academies offer robust upskilling and reskilling programs to help employees obtain certifications from providers like Snowflake. DXC's Data & AI offerings help customers benchmark, prioritize, select, and deploy the right infrastructure to leverage data as an asset and differentiator. DXC Consulting & Engineering Services' more than 50,000 engineers and specialized consultants build cloud environments tailored to each customer, resulting in accelerated migration, secured data, and maintenance optimization. The full 2025 ISG's Provider Lens™ Snowflake Ecosystem Partners 2025 study can be viewed here. For more information on DXC's Data & AI offerings, click here. About DXC Technology DXC Technology (NYSE: DXC) is a leading global provider of information technology services. We're a trusted operating partner to many of the world's most innovative organizations, building solutions that move industries and companies forward. Our engineering, consulting and technology experts help clients simplify, optimize and modernize their systems and processes, manage their most critical workloads, integrate AI-powered intelligence into their operations, and put security and trust at the forefront. Learn more on About ISG ISG (Information Services Group) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world's top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. For more information, please visit:
Cision Canada
18 minutes ago
- Cision Canada
Tax Tip - Make the most of your first home savings account Français
OTTAWA, ON, July 22, 2025 /CNW/ - A First Home Savings Account (FHSA) lets you save for a qualifying home with tax-free growth and tax-deductible contributions, making it a great option for potential first-time home buyers. But, it's important to make sure you don't put too much into your FHSA. If you do, part of the tax-free growth you're generating could end up going toward taxes anyway! Here are some tips for how you can make the most of your FHSA and avoid any costly errors: Make sure you're eligible FHSAs are intended for people who are saving for their first home – it's right in the name! You can only open an account if you're an adult resident of Canada and a first-time home buyer. Pro tip: To be considered a first-time home buyer, you can't have lived in a home you owned, or shared ownership of, in the past four years. If you have a spouse or common-law partner, you can't have lived in a home they own either. Understand your participation room Participation room is the total amount your FHSA can hold in a given year. When you open your first FHSA, your participation room is $8,000. Pro tip: Unlike a tax-free savings account, your FHSA participation room only starts when you officially open your first account through your financial institution. You can participate in your FHSA by making contributions from your income or other sources, or you can make transfers from your registered retirement savings plan (RRSP). Pro tip: No matter how you choose to participate, the maximum participation room in your account for the first year is $8,000. Each year after your account was opened, you will get another $8,000 of participation room, as long as you stay within your limit each year. The lifetime limit for FHSAs is $40,000. If you don't end up using all of your participation room for that year by December 31, you may be able to use it the following year. You can open more than one FHSA, but having more than one account doesn't mean you get extra participation room. The total room across all your FHSAs will still be $8,000 in the first year, followed by an additional $8,000 each following year, as long as you stay within your limit, up to a lifetime maximum of $40,000. Once you open your first FHSA and file your taxes for that year, you will get a statement on your notice of assessment that lets you know how much participation room you have. You can also find this statement in your CRA account. Don't over-participate Over-participation is what happens when you contribute or transfer more into your FHSA(s) than your participation room for that year. Pro tip: Any amount that exceeds your participation room is called an "excess amount" and it may be taxed. If you over-participate, it affects your participation room for the following year. Any excess amounts will reduce your participation room for the next year. For example, if you opened an FHSA in 2024 and contributed $10,000, your participation room for 2025 will only be $6,000. Don't wait! You will have to pay tax on any excess amount you have in your FHSA every month. Take swift action to resolve the issue – don't let your growth be impacted by taxes! More on this below. Fix your over-participation as soon as possible If you made contributions from your income or other sources to your FHSA, you can make a designated withdrawal to reduce the excess and get your account back within the annual limit. Pro tip: To make a designated withdrawal, fill out form RC727 and give it to your financial institution. If you transferred into your FHSA from your RRSP, you can make a designated transfer to return the excess amount to your RRSP. Pro tip: To make a designated transfer, you also need to fill out form RC727 and give it to your financial institution. You can also remove the excess from your FHSA by withdrawing that amount, but when you do this, it will be considered a taxable withdrawal. Just like it sounds, that means you have to pay income tax on the amount you remove, because it is now considered income. If you have an excess FHSA amount, you have to report it by filling out form RC728 and form RC728-SCH-A. This will determine how much tax you need to pay. If you don't file these forms on time, the CRA may send you a notice of assessment. Pro tip: Sign up for email notifications in your CRA account to get notified every time the CRA sends you mail. Use the Canada Revenue Agency's FHSA estimators There are two FHSA estimators. The first gives you an idea of how much you could save for a down payment, including possible investment growth. The second looks at your potential tax savings, based on your yearly taxable income and province or territory of residence. The estimators have built-in limits to reflect the annual participation room of $8,000 and the $40,000 lifetime limit. These are great tools to try out when planning your FHSA participation. Looking for more information? FHSA statistics for 2023 are available on including how many people opened accounts, the average balance, and the total value of all active accounts. Data for the 2024 tax year is being processed and will be added to this page when available. For more details on how FHSAs work, visit First Home Savings Account on Contacts Media Relations Canada Revenue Agency 613-948-8366 [email protected] Stay connected Follow the CRA on Facebook Follow the CRA on X – @ CanRevAgency Follow the CRA on LinkedIn Follow the CRA on Instagram Subscribe to a CRA electronic mailing list Add our RSS feeds to your feed reader Watch our tax-related videos on YouTube Listen to our Taxology podcast SOURCE Canada Revenue Agency
Cision Canada
18 minutes ago
- Cision Canada
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
NEW YORK, /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth. The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma, is a significant factor driving the adoption of AI in ophthalmology. As the population ages, the incidence of these diseases increases, creating a need for efficient and accurate diagnostic tools. For instance, according to the CDC, the estimated number of Americans living with glaucoma in 2022 was 4.22 million. AI algorithms can rapidly analyze complex retinal images, facilitating early detection and treatment. For instance, AI systems have shown high sensitivity and specificity in identifying diabetic retinopathy, which allows for timely interventions and reduces the risk of vision loss. Moreover, integrating advanced imaging techniques such as Optical Coherence Tomography (OCT) with AI has revolutionized ophthalmic diagnostics. High-resolution imaging provides detailed views of ocular structures, which enhances diagnostic precision when analyzed by artificial intelligence (AI). The availability of large datasets from these imaging technologies allows for the training of robust AI models, improving their accuracy and reliability in clinical settings." Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB: AVAI), Alcon Inc. (NYSE: ALC), Bausch + Lomb Corporation (NYSE: BLCO), Johnson & Johnson (NYSE: JNJ), Tempus AI, Inc. (NASDAQ: TEM). Research And Markets continued: "Furthermore, teleophthalmology, the remote delivery of eye care services, has gained traction, especially in underserved regions. AI is crucial in this expansion by enabling automated analysis of retinal images, facilitating remote diagnosis, and reducing the need for in-person consultations. This approach increases access to eye care and optimizes resource utilization in healthcare systems. For instance, in June 2024, C3 Med-Tech, an ophthalmic health tech startup, raised USD 0.23 million to launch AI-enabled, portable eye screening devices. The funding is expected to support telemedicine integration, real-time disease detection, and expansion across India, aiming to reduce avoidable blindness, especially in underserved communities facing a shortage of ophthalmologists. Moreover, AI's ability to analyze and interpret data from Electronic Health Records (EHRs) facilitates personalized treatment plans in ophthalmology. AI predicts disease progression by assessing patient history, genetic information, and imaging data and recommends tailored interventions, further contributing to market growth." Avant Technologies, Inc. (OTCQB: AVAI) Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference - Avant Technologies, Inc. ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Cartagena, Colombia. The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in Latin America. Ainnova's CEO, Vinicio Vargas, who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego, Hugo Ocampo, and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems. In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova's AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy. If the program is successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through AAC. AAC has the worldwide licensing rights for Ainnova's technology portfolio, which includes Ainnova's Vision AI platform. In other diabetes developments and happenings in the biotech market include: Alcon Inc. (NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, recently announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. "Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone," said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. "We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients." Bausch + Lomb Corporation (NYSE: BLCO), a leading global eye health company dedicated to helping people see better to live better, recently launched"Eyes Tell the Story: The Impact of Dry Eye." The campaign aims to educate about dry eye through personal stories, compelling imagery and new survey data, and encourages people with symptoms to speak with their eye doctor to find relief. Eyes Tell the Story builds upon Know Your Dry Eye, an educational campaign launched in 2024 that featured data and insights from the company's first State of Dry Eye survey, which showed the majority of Americans may not know that their eye symptoms are associated with eye dryness, despite the growing prevalence of dry eye. This year's survey, conducted among dry eye sufferers who are using either a prescription treatment or over-the-counter (OTC) product, further supports the need for more patient education and to dispel ongoing misconceptions surrounding dry eye. Johnson & Johnson (NYSE: JNJ) recently launched TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The TECNIS Odyssey IOL was first launched in the US in October 2024. The TECNIS Odyssey IOL is a full vision range intraocular lens (IOL), built on the TECNIS platform from Johnson & Johnson, which, according to the company, provides 2 times better contrast in low lighting than PanOptix. The TECNIS Odyssey combines advanced optics and proprietary materials, offering consistently clear, high-contrast vision, according to the company. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared ECG-AI device in Tempus' growing suite of next generation devices designed to identify patients at risk for a variety of cardiovascular conditions. "With Tempus ECG-Low EF, we're adding another powerful tool to the hands of clinicians to help them identify patients at risk for serious cardiovascular conditions much earlier in their care journey," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. "Detection of LVEF is essential for undiagnosed patients, and this technology enables us to deliver that capability at scale to transform patient care. The addition of a second FDA-cleared Tempus ECG-AI solution reflects our continued commitment to advancing AI-driven cardiology." DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
